$2.6 Billion is the total value of Rock Springs Capital Management LP's 147 reported holdings in Q2 2018. The portfolio turnover from Q1 2018 to Q2 2018 was - .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
WST | New | WEST PHARMACEUTICAL SVSC INC | $15,886,000 | – | 160,000 | +100.0% | 0.61% | – |
TBIO | New | TRANSLATE BIO INC | $12,790,000 | – | 1,011,079 | +100.0% | 0.49% | – |
ARGX | New | ARGENX SEsponsored adr | $10,668,000 | – | 128,750 | +100.0% | 0.41% | – |
APTX | New | APTINYX INC | $8,218,000 | – | 340,000 | +100.0% | 0.32% | – |
BSX | New | BOSTON SCIENTIFIC CORP | $5,641,000 | – | 172,500 | +100.0% | 0.22% | – |
EVHC | New | ENVISION HEALTHCARE CORP | $4,854,000 | – | 110,300 | +100.0% | 0.19% | – |
CORV | New | CORREVIO PHARMA CORP | $4,536,000 | – | 1,200,000 | +100.0% | 0.18% | – |
KNSA | New | KINIKSA PHARMACEUTICALS LTD | $1,562,000 | – | 90,000 | +100.0% | 0.06% | – |
New | NEUROCRINE BIOSCIENCES INCnote 2.250% 5/1 | $1,446,000 | – | 1,000,000 | +100.0% | 0.06% | – | |
New | DERMIRA INCnote 3.000% 5/1 | $827,000 | – | 1,000,000 | +100.0% | 0.03% | – | |
MCK | New | MCKESSON CORP | $667,000 | – | 5,000 | +100.0% | 0.03% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-08-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
INTUITIVE SURGICAL INC | 40 | Q3 2023 | 3.4% |
NEUROCRINE BIOSCIENCES INC | 39 | Q3 2023 | 4.8% |
PACIRA PHARMACEUTICALS INC | 39 | Q3 2023 | 2.6% |
ULTRAGENYX PHARMACEUTICAL IN | 39 | Q3 2023 | 1.9% |
ACADIA HEALTHCARE COMPANY IN | 38 | Q3 2023 | 4.4% |
ASCENDIS PHARMA A/S | 35 | Q3 2023 | 1.3% |
INVITAE CORP | 35 | Q3 2023 | 1.8% |
BIOMARIN PHARMACEUTICAL INC | 35 | Q3 2023 | 1.3% |
MACROGENICS INC | 35 | Q3 2023 | 0.5% |
COLLEGIUM PHARMACEUTICAL INC | 34 | Q3 2023 | 2.1% |
View Rock Springs Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Aeglea BioTherapeutics, Inc. | February 14, 2023 | 3,413,906 | 5.6% |
Compass Therapeutics, Inc. | February 14, 2023 | 5,333,188 | 4.2% |
Mirum Pharmaceuticals, Inc. | February 14, 2023 | 1,795,733 | 4.9% |
PhaseBio Pharmaceuticals IncSold out | February 14, 2023 | 0 | 0.0% |
Sierra Oncology, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
ARDELYX, INC.Sold out | February 15, 2022 | 0 | 0.0% |
CHIASMA, INCSold out | February 15, 2022 | 0 | 0.0% |
FIVE PRIME THERAPEUTICS, INC.Sold out | February 15, 2022 | 0 | 0.0% |
F-star Therapeutics, Inc. | February 15, 2022 | 751,889 | 3.6% |
Protara Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
View Rock Springs Capital Management LP's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-05-15 |
SC 13G | 2024-05-01 |
SC 13G/A | 2024-04-05 |
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
View Rock Springs Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.